Cited by 323Alzheimer's disease research and treatmentsPrion Diseases and Protein MisfoldingParkinson's Disease Mechanisms and Treatments

Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration

Open access
Goedert, Michel, Masuda-Suzukake, Masami, Falcon, Benjamin·2017·Brain

Abstract

The abnormal aggregation of a small number of known proteins underlies the most common human neurodegenerative diseases. In tauopathies and synucleinopathies, the normally soluble intracellular proteins tau and α-synuclein become insoluble and filamentous. In recent years, non-cell autonomous mechanisms of aggregate formation have come to the fore, suggesting that nucleation-dependent aggregation may occur in a localized fashion in human tauopathies and synucleinopathies, followed by seed-dependent propagation. There is a long prodromal phase between the formation of protein aggregates and the appearance of the first clinical symptoms, which manifest only after extensive propagation, opening novel therapeutic avenues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/aww230

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An earlier event in Alzheimer's disease is pronounced neuron loss in the locus coeruleus, a site of neuromelanin accumulation and the first site to develop tau neurofibrillary tangles.

    “But an earlier event is pronounced neuron loss in the locus coeruleus, a site of neuromelanin accumulation and the first site to develop the intracellular inclusions of tau protein termed neurofibrillary tangles (250, 251).”

    From Chemiexcitation: Mammalian Photochemistry in the Dark<sup>†</sup> (2023) · cites this paper as [250]

    The Introduction (page unavailable) places tau inclusions in the locus coeruleus at early stages of Alzheimer’s disease. It does not report pronounced neuron loss or neuromelanin accumulation there, and it names the transentorhinal cortex—not the locus coeruleus—as the proposed single starting site for Alzheimer’s tau inclusions. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond M. Transcellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012; 287: 19440-51.
  2. Sto ¨hr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, et al. Purified and synthetic Alzheimer's amyloidb (Ab) prions. Proc Natl Acad Sci USA 2012; 109: 11025-30.
  3. Stokholm MS, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological alpha-synuclein in gastrointestinal tissues from pro- dromal Parkinson's disease patients. Ann Neurol 2016; 79: 940-9.

Cited by

Sorted by citations

Authors
Goedert, M., Masuda-Suzukake, M., & Falcon, B.
Affiliations
MRC Laboratory of Molecular Biology (GB)
Corresponding author
Goedert, Michel
Venue
Brain
Published
2016-09-21
Volume
140
Issue
2
Pages
266-278
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2521817318
Cited by
323
References
124
Citations by year
2026: 27 · 2025: 30 · 2024: 27 · 2023: 15 · 2022: 29 · 2021: 38 · 2020: 45 · 2019: 35 · 2018: 36 · 2017: 39 · 2016: 1
FWCI
4.34
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Medical Research Council (MC-U105184291, MC_EX_MR/N027892/1)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
tau protein, alpha-synuclein, protein aggregation, neurodegeneration, tauopathy, synucleinopathies, prion-like propagation, prodromal symptoms, therapeutic target
MeSH terms
Prion Proteins, Animals, Humans, tau Proteins, Neurodegenerative Diseases, alpha-Synuclein, Protein Aggregation, Pathological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review